|Table of Contents|

Analysis of influencing factors of positive prostate biopsy in patients with PSA<20 ng/mL

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
503-507
Research Field:
Publishing date:

Info

Title:
Analysis of influencing factors of positive prostate biopsy in patients with PSA<20 ng/mL
Author(s):
PENG Guizhong1 ; LI Yuanwei1; ZENG Yiming1; LI Zonglin1; YANG Yongjun1; LU Qiang1; LIU Peng1; LIU Yu1; ZHAO Kang1; LU Jun2
1.The First Affiliated Hospital of Hunan Normal University/Hunan Provincial People's Hospital,Hunan Changsha 410005,China;2.Department of Urology,Taoyuan People's Hospital,Hunan Taoyuan 415700,China.
Keywords:
prostate cancer; prostate biopsy; PSA; influencing factors
PACS:
R737.25
DOI:
10.3969/j.issn.1672-4992.2024.03.020
Abstract:
Objective:To analyze the factors influencing the positive rate of prostate biopsy in patients with PSA levels below 20 ng/mL.Methods:Data from patients who underwent prostate biopsy at Hunan Provincial People's Hospital between April 2019 and April 2023 were retrospectively analyzed using the hospital's specialized disease database.Patients with PSA levels below 20 ng/mL were included in the study.Initially,single-factor analysis was conducted to identify factors that positively influenced the biopsy results.Subsequently,multivariate analysis was performed to analyze the identified factors.Finally,a ROC curve was generated to validate the study's objective.Results:Among the 67 patients,35(52.24%)were diagnosed with prostate cancer,while 32(47.76%)were diagnosed with non-prostate cancer.Univariate analysis revealed significant differences in f/tPSA,PI-PADS score,and puncture approach between the prostate cancer and non-prostate cancer groups.However,no significant differences were observed in fPSA,age,tPSA,PV,and PSAD.In the positive biopsy group,f/tPSA levels were lower(54.29% vs 25.00%),PI-PADS scores were higher(42.86% vs 0.00%),and the transperineal puncture route was more frequently used(48.57% vs 21.88%).Multivariate analysis identified f/tPSA and PI-PADS as influencing factors for biopsy results.ROC curve analysis was performed for these factors and their combination(f/tPSA,PI-PADS) to determine their predictive value for biopsy results.The diagnostic value of f/tPSA for biopsy results was slightly lower(P＜0.05) but statistically significant.The AUC of PI-PADS was 0.731,indicating its high diagnostic value for puncture results(P＜0.05).Moreover,the AUC of the combined indicators(f/tPSA,PI-PADS) was 0.775,demonstrating their high diagnostic value for prostate biopsy results(P＜0.05) with significant statistical significance.Conclusion:In patients with PSA levels below 20 ng/mL,the PI-PADS score,f/tPSA,and the combination of PI-PADS and f/tPSA are important factors influencing positive prostate biopsy outcomes.

References:

[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2]ZHU Y,MO M,WEI Y,et al.Epidemiology and genomics of prostate cancer in Asian men［J］.Nat Rev Urol,2021,18(5):282-301.
[3]ESAI MM,CACCIAMANI GE,GILL K,et al.Trends in incidence of metastatic prostate cancer in the US［J］.JAMA Netw Open,2022,5(3):e222246.
[4]LONERGAN PE,JEONG CW,WASHINGTON SL,et al.Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL:pathological outcome analysis of a population-level database［J］.Prostate Cancer and Prostatic Diseases,2022,25(4):690-693.
[5]HYUNG MC,USYN H,YONGHYUN P,et al.Combined MRI and PSA strategy improves biopsy decisions compared with PSA only:Longitudinal observations of a cohort of patients with a PSA level less than 20 ng/mL［J］.Academic Radiology,2022,30(3):509-515.
[6]JOHN T WEI,DANIEL BAROCAS,SIGRID CARLSSON,et al.Early detection of prostate cancer:AUA/SUO guideline part II:Considerations for a prostate biopsy［J］.The Journal of Urology,2023,210(1):101097JU0000000000003492.
[7]GIORGIO G,RICCARDO L,FREDDIE B,et al.Epidemiology and prevention of prostate cancer［J］.European Urology Oncology,2021,4(6):877-892.
[8]国家癌症中心,国家肿瘤质控中心前列腺癌质控专家委员会.中国前列腺癌规范诊疗质量控制指标(2022版)［J］.中华肿瘤杂志,2022,44(10):1011-1016. National Cancer Centre,Expert Committee of Pca Quality control of National Cancer Quality Control Center.Quality control indicators for standardized diagnosis and treatment of prostate cancer in China(2022 edition)［J］.Chin J Cancer,2021,44(10):1011-1016.
[9]XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants［J］.Chinese Medical Journal,2022,135(5):584-590.
[10]YASUHIRO Y,TAKUMI S,AKIHISA U,et al.Magnetic resonance imaging-guided targeted prostate biopsy:Comparison between computer-software-based fusion versus cognitive fusion technique in biopsy-naive patients［J］.International Journal of Urology,2020,27(1):67-71.
[11]CONSTANTIN T,SAVU DA,BUCUR,et al.The role and significance of bioumoral markers in prostate cancer［J］.Cancers,2021,13(23):5932.
[12]MAMELLO S,KEAMOGETSWE R,PABLLO M,et al.Prostate cancer review:Genetics,diagnosis,treatment options,and alternative approaches［J］.Molecules,2022,27(17):5730.
[13]张杰.影响PSA 4～20ng/ml区间前列腺穿刺结果的多因素分析［D］.芜湖：皖南医学院,2019. ZHANG J.Analysis of multiple factors influencing the results of prostate puncture with PSA range from 4～20ng/ml［D］.Wuhu:Wannan Medical College,2019.
[14]JIAHAO S,XINYU G,ZIYANG L,et al.Clinical research analysis based on prostate cancer screening diagnosis［J］.Andrologia,2022,54(4):1-8.
[15]黄健.中国泌尿外科和男科疾病诊断治疗指南（2022版）［M］.北京:科学出版社,2022：130-216. HUANG J.Chinese guidelines for the diagnosis and treatment of urological and andrological diseases(2022 edition)［M］.Beijing:Science Press,2022:130-216.
[16]AMR N，HESHAM M，RASHA S，et al.Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy naive patients with suspicious prostate cancer［J］.Arab Journal of Urology,2022,20(3):121-125.
[17]MICHAEL B,QUENTIN B,BASTIEN G,et al.MRI-targeted biopsy for detecting prostate cancer:Have the guidelines changed our practices and our prostate cancer detection rate［J］.International Urology and Nephrology,2020,52(4):611-618.
[18]XUE L,CHUNMEI L,MIN C.Patients with "Gray Zone" PSA levels:Application of prostate MRI and MRS in the diagnosis of prostate cancer［J］.Journal of Magnetic Resonance Imaging,2022,57(4):992-1010.
[19]BHOJWANI A,DESAI C,EHSANULLAH S A,et al.912 comparison of magnetic resonance imaging cognitive prostate biopsy versus magnetic resonance imaging-ultrasound fusion prostate biopsy in the detection of prostate cancer［J］.British Journal of Surgery,2021,108(Supplement_2):znab134.588.
[20]BAKS,BUDZEN K,WESOLOWSKI P,et al.Review of diagnostic methods for prostate cancer with consideration of MRI-TRUS fusion biopsy［J］.Journal of Education,Health and Sport,2022,12(9):720-728.
[21]HSIEH PF,CHANG TY,LIN WC,et al.A comparative study of transperineal software-assisted magnetic resonance/ultrasound fusion biopsy and transrectal cognitive fusion biopsy of the prostate［J］.BMC Urology,2022,22(1):1-8.

Memo

Memo:
湖南省卫生健康委一般指导课题（编号：D202304057410）
Last Update: 2023-12-29